Astria Therapeutics (NASDAQ:ATXS - Get Free Report) had its price objective lifted by investment analysts at JMP Securities from $25.00 to $26.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a "market outperform" rating on the biotechnology company's stock. JMP Securities' target price indicates a potential upside of 283.48% from the stock's current price.
ATXS has been the subject of a number of other reports. HC Wainwright reaffirmed a "buy" rating and set a $16.00 price target on shares of Astria Therapeutics in a report on Wednesday, August 13th. Citigroup restated an "outperform" rating on shares of Astria Therapeutics in a report on Wednesday, August 13th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $47.00 target price on shares of Astria Therapeutics in a report on Wednesday, May 14th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $29.00.
View Our Latest Analysis on ATXS
Astria Therapeutics Stock Performance
Shares of Astria Therapeutics stock traded down $0.07 during trading hours on Wednesday, reaching $6.78. 232,942 shares of the company were exchanged, compared to its average volume of 360,393. Astria Therapeutics has a 1 year low of $3.56 and a 1 year high of $12.92. The firm has a market cap of $382.66 million, a PE ratio of -3.37 and a beta of 0.48. The stock's fifty day moving average is $6.23 and its 200 day moving average is $5.74.
Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.04. Research analysts expect that Astria Therapeutics will post -1.65 earnings per share for the current year.
Hedge Funds Weigh In On Astria Therapeutics
Institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC increased its stake in shares of Astria Therapeutics by 109.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock worth $47,000 after acquiring an additional 2,766 shares during the period. Farther Finance Advisors LLC increased its position in Astria Therapeutics by 185.8% during the 2nd quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 3,557 shares during the period. BNP Paribas Financial Markets purchased a new position in shares of Astria Therapeutics during the 4th quarter worth approximately $50,000. Virtus ETF Advisers LLC purchased a new position in shares of Astria Therapeutics during the 4th quarter worth approximately $65,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Astria Therapeutics by 1,127.4% in the 1st quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company's stock valued at $46,000 after buying an additional 7,971 shares during the period. 98.98% of the stock is owned by institutional investors and hedge funds.
Astria Therapeutics Company Profile
(
Get Free Report)
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
See Also
Before you consider Astria Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astria Therapeutics wasn't on the list.
While Astria Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access